Hematology-American Society of Hematology Education Program

Article	Citations
Diagnosis and therapeutic decision-making for the neutropenic patient	61
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	58
Your chemo is no good here: management of high-risk MCL	54
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	36
Neurological manifestations of MGUS	35
On the horizon: upcoming new agents for the management of ITP	33
Anticoagulation at the end of life: whether, when, and how to treat	33
Labor and delivery: DIC, HELLP, preeclampsia	30
Mastocytosis demystified	29
Recognizing, defining, and managing CAR-T hematologic toxicities	26
Inpatient recognition and management of HLH	26
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	26
Bispecific antibody therapies	25
Has PD-1 blockade changed the standard of care for cHL?	25
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	24
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	24
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	23
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	22
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	22
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	22
Selecting initial therapy in CLL	21
Divergent paths: management of early relapsed follicular lymphoma	21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	20
New approaches to tackle cytopenic myelofibrosis	19
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	19

MGCS: where do we stand today?	18
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	18
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	18
How to recognize and manage COVID-19-associated coagulopathy	18
Fitness and frailty in myeloma	18
BV and beyond: how to incorporate novel agents into PTCL management	17
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	17
How to assess hemostasis in patients with severe liver disease	17
Optimizing outcomes in secondary AML	17
How to manage hemostasis in patients with liver disease during interventions	17
Troubleshooting heparin resistance	17
How to diagnose and manage antiphospholipid syndrome	17
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	17
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	16
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	16
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	16
Hemophilia gene therapy: ushering in a new treatment paradigm?	16
Running interferon interference in treating PV/ET: meeting unmet needs	16
Management of TKI-resistant chronic phase CML	16
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	16
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	16
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	15
Hematology 2022—what is complete HLA match in 2022?	15
Consumptive coagulopathy in the ICU	15
Special considerations in GI bleeding in VWD patients	14
Management of limited-stage Hodgkin lymphoma	14
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	13
What to use to treat AML: the role of emerging therapies	13
Demystifying autoimmune HIT: what it is, when to test, and how to treat	13
Managing therapy-associated neurotoxicity in children with ALL	13
Management of marginal zone lymphomas	13
Atypical CML: diagnosis and treatment	13
How to manage bleeding disorders in aging patients needing surgery	13
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	12
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	12
Infectious complications and vaccines	12
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	12
Thrombosis questions from the inpatient wards	12
Approaches to management of HIT in complex scenarios, including cardiac surgery	12
Organ function indications and potential improvements following curative therapy for sickle cell disease	11
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	11
Alloimmunization and hyperhemolysis in sickle cell disease	11
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	11
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	11
Lower risk but high risk	11
When does a PNH clone have clinical significance?	11
Transplant in AML with measurable residual disease: proceed or defer?	11
CNS prophylaxis in aggressive B-cell lymphoma	11
Thrombocytopenia in pregnancy	11
Cytoreduction for ET and PV: who, what, when, and how?	10

How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	10
What makes a pediatric or young adult patient an appropriate transplant candidate?	10
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	10
Treatment of VTE in the thrombocytopenic cancer patient	10
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	10
Pegylated interferon: the who, why, and how	10
What is the ideal approach—doublet, triplet, or quadruplet(s)?	10
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	10
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	9
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	9
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	9
Novel therapies upon failure of HMA plus venetoclax	9
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	9
Clinical manifestations of telomere biology disorders in adults	9
Frontline treatment in CLL: the case for time-limited treatment	9
Whom should we treat with novel agents? Specific indications for specific and challenging populations	9
Next-generation therapy for lower-risk MDS	9
Ph− ALL: immunotherapy in upfront treatment	9
Managing side effects: guidance for use of immunotherapies in multiple myeloma	9
IV iron formulations and use in adults	8
Treatment of older adult or frail patients with multiple myeloma	8
The role of stem cell transplant (auto and allo) in PTCL and CTCL	8
Approach to the patient with suspected hypereosinophilic syndrome	8
Sequencing bispecific antibodies and CAR T cells for FL	8
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	8
In 2022, which is preferred: haploidentical or cord transplant?	8
Should we use bisphosphonates to treat bone complications in sickle cell disease?	8
Warm autoimmune hemolytic anemia and the best treatment strategies	8
Barriers to accessing cellular therapy for patients receiving care in community practices	8
Diamond-Blackfan anemia	8
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	8
What else do I need to worry about when treating graft-versus-host disease?	8
Porphyria cutanea tarda: a unique iron-related disorder	8
The approach of HMA plus VEN with or without BMT for all patients with AML	7
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	7
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	7
Long-term prophylaxis: what are our options and how to define success?	7
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	7
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	7
Immunology 101: fundamental immunology for the practicing hematologist	7
When should we use it? The role of brentuximab vedotin in 2024	7
Diagnosis and clinical management of enzymopathies	7
Psychosocial and financial issues after hematopoietic cell transplantation	7
Clonal hematopoiesis in frequent whole blood donors	7
von Willebrand disease and heavy menstrual bleeding: when and how to test	7
Are transplant indications changing for myelofibrosis?	7
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	7
Sequencing therapy in relapsed DLBCL	7
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	7
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	6
Diagnosis and clinical management of red cell membrane disorders	6
Heparin-induced thrombocytopenia and cardiovascular surgery	6
Multiple myeloma: a paradigm for blending community and academic care	6
Risk-stratification in frontline CLL therapy: standard of care	6
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	6
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	6
COVID-19 and thrombosis: searching for evidence	6
The intersection of sickle cell disease, stigma, and pain in Africa	6
New definitions for antiphospholipid syndrome: ready for clinical use?	6
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	6
Management of Fanconi anemia beyond childhood	6
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	6
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	6
Newborn screening initiatives for sickle cell disease in Africa	6
Novel platelet products including cold-stored platelets	6
Amyloid consults do not have to be vexing	6
Using disease-modifying therapies in sickle cell disease	6
Acute lymphoblastic leukemia in young adults: which up-front treatment?	5
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	5
Clonal evolution in inherited marrow failure syndromes predicts disease progression	5
Maintenance strategies for relapse prevention and treatment	5
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	5
Potential and emerging therapeutics for HHT	5
Management of hemolytic transfusion reactions	5
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	5
Renal manifestations of MGUS	5
New investigational combinations for higher-risk MDS	5
When to consider inherited marrow failure syndromes in adults	5
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	5
Challenges to successful outcomes in AYAs with ALL and potential solutions	5

Cryptogenic oozers and bruisers	5
Novel clinical care models for patients with sickle cell disease	5
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.	5
The first relapse in multiple myeloma: how to pick the next best thing	5
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	5
Double-hit lymphoma: optimizing therapy	5
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	5
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	5
Transplantation in CML in the TKI era: who, when, and how?	5
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.	4
Cellular therapy for multiple myeloma: what's now and what's next	4
Ph+ ALL in 2022: is there an optimal approach?	4
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	4
Epidemiology and treatment of priapism in sickle cell disease	4
Late complications and long-term care of adult CAR T-cell patients	4
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.	4
How immunodeficiency can lead to malignancy	4
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	4
High-risk multiple myeloma: how to treat at diagnosis and relapse?	4
Current use of bispecific antibodies to treat multiple myeloma	4
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	4
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	4
How to manage ITP with life-threatening bleeding	4
Ph+ ALL: new approaches for upfront therapy	4
Sickle cell disease in India: the journey and hope for the future	4
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	4
Unexplained arterial thrombosis: approach to diagnosis and treatment	4
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	4
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	3
Acute GVHD: think before you treat	3
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	3
Passive immune therapies: another tool against COVID-19	3
Pyruvate kinase activators: targeting red cell metabolism in thalassemia	3
Mutational screening to improve the transplantation decision-making process in MDS	3
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	3
Givosiran: a targeted treatment for acute intermittent porphyria	3
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	3
Optimal approach to T-cell ALL	3
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	3
Perioperative consultative hematology: can you clear my patient for a procedure?	3
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	3
Identifying and treating iron deficiency anemia in pregnancy	3
Platelet components and bacterial contamination: hospital perspective 2022	3
AL amyloidosis: untangling new therapies	3
Dual-targeted regimens for the frontline treatment of CLL	3
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	3
Approaches to optimize outcomes in transplant recipients	3
Novel approaches to acute graft-versus-host disease prevention	3
Modified T cells as therapeutic agents	3